
Revvity, Inc.
RVTYRevvity, Inc. (RVTY) is a global provider of laboratory testing, diagnostic products, and healthcare solutions. The company focuses on advancing scientific research and medical diagnostics through innovative technologies and comprehensive testing services, supporting healthcare providers and research institutions worldwide.
Dividend History
Investors can expect a dividend payout of $0.07 per share, scheduled to be distributed in 14 days on February 6, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| February 6, 2026 | $0.07 | 2026-01-16 | 2026-01-16 |
| November 7, 2025 | $0.07 | 2025-10-17 | 2025-10-17 |
| August 8, 2025 | $0.07 | 2025-07-18 | 2025-07-18 |
| May 9, 2025 | $0.07 | 2025-04-17 | 2025-04-18 |
| February 7, 2025 | $0.07 | 2025-01-17 | 2025-01-17 |
Dividends Summary
- Consistent Payer: Revvity, Inc. has rewarded shareholders with 89 dividend payments over the past 22 years.
- Total Returned Value: Investors who held RVTY shares during this period received a total of $6.23 per share in dividend income.
- Latest Payout: The most recent dividend of $0.07/share was paid 77 days ago, on November 7, 2025.
- Yield & Schedule: RVTY currently pays dividends quarterly with an annual yield of 0.24%.
- Dividend Growth: Since 2004, the dividend payout has grown by 0.0%, from $0.07 to $0.07.
- Dividend Reliability: RVTY has maintained or increased its dividend for 89 consecutive payments.
Company News
U.S. stock futures declined on Tuesday ahead of December CPI data release. Major indices were trading lower with the S&P 500 down 0.12% and Nasdaq 100 down 0.19%. Key stocks in focus include Alphabet reaching $4 trillion market value, JPMorgan preparing to report Q4 earnings, Five9 expanding its Google Cloud partnership, and Revvity rising 4.92% ...
Wall Street extended its record-setting streak with major indices hitting all-time highs after a breakthrough in US-China trade negotiations. Trade tensions eased with potential tariff threats averted and promising discussions between diplomatic representatives.
Revvity reported Q2 earnings beating estimates but lowered fiscal year 2025 guidance due to challenging macroeconomic conditions and China's new hospital laboratory reimbursement policy, which is impacting its immunodiagnostics business.
Revvity reported Q2 2025 financial results with $720 million revenue, exceeding estimates, but experiencing margin compression and slight earnings decline due to tariff pressures and challenging market conditions.
The global CRISPR gene editing market is projected to grow from USD 4.15 billion in 2024 to USD 16.47 billion by 2034, driven by technological advancements, increasing investments, and growing applications in biotechnology and healthcare.









